Hikma admits that there continues to be “a lot of factors to evaluate whether we want to go on our own or not” for its proposed generic version of Jazz Pharmaceuticals’ Xyrem (sodium oxybate) 0.5g/ml oral solution, after the company’s authorized generic gave a better than expected boost following its introduction at the beginning of this year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?